Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Ragweed SLIT tablets improve asthma outcome scores in patients with allergic rhinoconjunctivitis

Key clinical point: Pediatric patients with allergic rhinoconjunctivitis taking ragweed sublingual immunotherapy (SLIT) tablets had better asthma outcome scores, compared with placebo.

Major finding: In the group receiving SLIT tablets, asthma daily symptom scores improved by 30.7% during the peak of the season and by 23.1% during the whole season.

Study details: An international, double-blind, placebo-controlled trial of 1,022 children with allergic rhinoconjunctivitis with and without asthma receiving ragweed SLIT tablets or placebo for 28 weeks.

Disclosures: This trial was funded by Merck, the developers of Ragwitek. The authors received medical writing and editing assistance from Scott Medical Communications, LLC, which was funded by ALK. Dr. Bernstein reports being on the advisory board for ALK America and GlaxoSmithKline; a consultant for Gerson-Lehman and Guidepoint Global; and received grant support from Aimmune, ALK, Amgen, AstraZeneca, Avillion, Biocryst, Boehringer Ingelheim, Cipla, Genentech, GlaxoSmithKline, Gossamer, Leo, Lupin, Menlo, Merck, Mylan, Novartis, Novum, Pearl, Regeneron, Shire, and TEVA. The other authors reported no relevant conflicts of interest.


Source: Bernstein D et al. AAAAI 2020, Abstract 270.